David Jiménez is Associate Professor of Medicine at the University of Alcalá de Henares, Madrid, Spain, and Chief of the Venous Thromboembolism Programme at the Ramón y Cajal Hospital in Madrid. He serves as Chief of the Respiratory Department of Ramon y Cajal Hospital. He received his medical degree cum laude from the University of Alcalá de Henares.
Dr Jiménez’s interests include venous thromboembolism, and clinical care, education and research for patients with pulmonary embolism (PE). He is past President of the Vascular Sections of both the Spanish Society of Respiratory Medicine (SEPAR) and the Madrid Society of Respiratory Medicine (NEUMOMADRID), and actual President of the Pulmonary Embolism Group of the European Respiratory Society.
Dr Jimenez has participated as Principal Investigator of several randomized clinical trials on thromboembolic prophylaxis and treatment. His research activity focuses on risk stratification and treatment of patients with PE. He was the Chairman of the PROTECT (prognostic value of CT scan for the prognosis of hemodynamically stable patients with PE) and the AINEP (diclofenac for patients with submassive PE) studies, and was a member of the Steering Committee of the PEITHO trial, which assessed the eficacy and safety of thrombolytics in intermediate-risk patients with PE. He has published more than 250 articles in peer-review journals.
He is also a member of several journal editorial boards, and is a peer reviewer for New England Journal of Medicine, The Lancet, JAMA, the Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, or Chest.
Dr. Jimenez is co-chairman of the 10th edition of the Antithrombotic and Thrombolytic Therapy ACCP guidelines, coauthor of the 2019 ESC Guidelines for the management of PE, and has been invited as a speaker at several national and international congresses and in a number of major universities worldwide.